Built upon robust preclinical and clinical datasets, NVDX3 has potential to replace existing allogenic bone grafting materials - providing patients with complex comorbidities better bone fusion success Phase 2b/3 expected to begin enrollment in H2 2025 in the US Mont...
At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone healing Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique ‘off-the-shelf allogeneic matrix...
The EIB has signed an €18 million venture debt deal with Belgian biotech company Novadip funding innovation on its therapies for rare bone-related genetic diseases. Novadip will further develop its unique bone tissue...
1st US patient treated with an autologous cell-based product (NVD-003) in a rare pediatric disease Full enrollment of patients on track for year-end completion in allogeneic cell-derived product (NVD-X3) trial in patients with a distal radius fracture following...
Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024* MONT SAINT-GUIBERT, Belgium – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing...
Judy Ashworth, MD, Chief Medical Officer of Novadip Biosciences SA Mont Saint-Guibert, Belgium – December 27, 2022 – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with...
MONT SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single...
MONT SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single...
New investment to fuel continued growth of 3M³ platform for the development of products in tissue reconstruction and oncology Mont Saint-Guibert, Belgium – October 28, 2021 – Novadip Biosciences (“Novadip” or “the Company”), a clinical stage company developing...
Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion. Primary endpoint met, study validates autologous cell therapy 3M³ platform for bone regeneration and demonstrates manufacturing capabilitiesNext generation autologous...
Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003 Authorization to start clinical trial in the US granted for rare paediatric bone disease Mont-Saint-Guibert, Mar 4, 2021 (GlobeNewswire) – Novadip Biosciences (“Novadip”), a...
Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation – Dual designations granted for NVD-003 for the Treatment of Congenital Pseudarthrosis of the Tibia a serious and debilitating condition that primarily affects children...
We are very proud to be in the news today. “Le tibia d’un enfant guéri grâce à une greffe osseuse 3D” Check out the links below. https://www.rtbf.be/auvio/detail_jt-19h30?id=2687657&jwsource=cl (23 min 30) https://www.rtl.be/info/video/758892.aspx...
Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome Mont-Saint Guibert, Belgium, 4 June, 2020: Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage...
Read this interview (French article) of our CEO Denis Dufrane in the newspaper “Trends Tendances” of this May 13, 2020. Trends 13 mai 2020 Résultats encourageants pour Novadip dans la reconstruction osseuse
Read this French article about Novadip in the newspaper “L’Echo” of this May 13, 2020. L’Echo 13 mai 2020 Novadip progresse dans la reconstruction osseuse